logo image

HIV Molecular Immunology Database

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 62675

HXB2 Location  Gag(162-172)   Gag Epitope Map
View variants at this location
Epitope KAFSPEVIPMF   Epitope Alignment
Variants
{k}KAFSPEVIPMF   observed variant
{d}KAFSPEVIPMF   observed variant
KAFSPEVIPMF{a}   observed variant
{q}KAFSPEVIPMF   observed variant
{s}KAFSPEVIPMF   observed variant
{t}KAFSPEVIPMF   observed variant
{a}KAFSPEVIPMF   observed variant
KAFaPEVIPMF{t}   observed variant
KAFSPEVIPMF{g}   observed variant
KAFSPEVIPMF{t}   observed variant
rAFSPEVIPMF{a}   observed variant
KAFSPEVIPMF{n}   observed variant
KnFSPEVIPMF{v}   observed variant
KAFSPEVIPMF{q}   observed variant
KnFSPEVIPMF{t}   observed variant
KAFSPEVIPMF{v}   observed variant
rAFSPEVIPMF{t}   observed variant
KAFaPEVIPMF{q}   observed variant
rAFSPEVIPMF{q}   observed variant
KAFSPEVvPMF{a}   observed variant
KAFaPEVIPMF   observed variant
KAFSaEVvPMF   observed variant
KnFSPEVIPMF   observed variant
KAFqPEVIPMF   observed variant
KAFSPEiIPMF   observed variant
rAFSPEiIPMF   observed variant
KAFSPEtIPMF   observed variant
KAFSPEVvPMF   observed variant
rAFaPEVIPMF   observed variant
rAFSPEVIPMF   observed variant
rgFSPEVIPMF   observed variant
KAFcPEVIPMF   observed variant
KqFSPEVIPMF   observed variant
KAFtPEVIPMF   observed variant
KgFaPEVIPMF   observed variant
KgFSPEVIPMF   observed variant
KAFSaEVIPMF   observed variant
KAFmPEVIPMF   observed variant
KgFqPEVIPMF   observed variant
KeFSPEVIPMF   observed variant
KsFSPEtIPMF   observed variant
KdFSPEVIPMF   observed variant
KsFSPEVIPfF   observed variant
KgFrPEVIPMF   observed variant
KAFSPEcIPMF   observed variant
KAFnPEVIPMF   observed variant
KsFSPEVIPMF   observed variant
KAFvPEVIPMF   observed variant
KAFSPEcvPMF   observed variant
KtFSPEVIPMF   observed variant
KcFSPEVIPMF   observed variant
Epitope Name KF11
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 51 variant(s).


Variant ID.  4656
Epitope Seq.  {E}KAFSPEVIPMF
Variant Seq.  {k}KAFSPEVIPMF
Mutations E/K
Epitope Location E-1K
HXB2 Location E161K
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, kKAFSPEVIPMF (-1 to the start of epitope KF11) had an increased replicative capacity but did not have an increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones vs. without CTLs.


Variant ID.  4657
Epitope Seq.  {E}KAFSPEVIPMF
Variant Seq.  {d}KAFSPEVIPMF
Mutations E/D
Epitope Location E-1D
HXB2 Location E161D
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, dKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones vs. without CTLs.


Variant ID.  4658
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVIPMF{a}
Mutations S/A
Epitope Location S+1A
HXB2 Location S173A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVIPMF{a} (+1 to the end of epitope KF11) had a decreased replicative capacity.


Variant ID.  4659
Epitope Seq.  {E}KAFSPEVIPMF
Variant Seq.  {q}KAFSPEVIPMF
Mutations E/Q
Epitope Location E-1Q
HXB2 Location E161Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, qKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4660
Epitope Seq.  {E}KAFSPEVIPMF
Variant Seq.  {s}KAFSPEVIPMF
Mutations E/S
Epitope Location E-1S
HXB2 Location E161S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, sKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4661
Epitope Seq.  {E}KAFSPEVIPMF
Variant Seq.  {t}KAFSPEVIPMF
Mutations E/T
Epitope Location E-1T
HXB2 Location E161T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, tKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4662
Epitope Seq.  {E}KAFSPEVIPMF
Variant Seq.  {a}KAFSPEVIPMF
Mutations E/A
Epitope Location E-1A
HXB2 Location E161A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aKAFSPEVIPMF (-1 to the start of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4663
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFaPEVIPMF{t}
Mutations S/T S/A
Epitope Location S+1T S4A
HXB2 Location S173T S165A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFaPEVIPMFt (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4664
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVIPMF{g}
Mutations S/G
Epitope Location S+1G
HXB2 Location S173G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVIPMFg (+1 to the end of epitope KF11) had a decreased replicative capacity.


Variant ID.  4665
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVIPMF{t}
Mutations S/T
Epitope Location S+1T
HXB2 Location S173T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVIPMFt (+1 to the end of epitope KF11) had a decreased replicative capacity.


Variant ID.  4666
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  rAFSPEVIPMF{a}
Mutations S/A K/R
Epitope Location S+1A K1R
HXB2 Location S173A K162R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rAFSPEVIPMFa (+1 to the end of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4667
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVIPMF{n}
Mutations S/N
Epitope Location S+1N
HXB2 Location S173N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVIPMFn (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4668
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KnFSPEVIPMF{v}
Mutations S/V A/N
Epitope Location S+1V A2N
HXB2 Location S173V A163N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KnFSPEVIPMFv (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4669
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVIPMF{q}
Mutations S/Q
Epitope Location S+1Q
HXB2 Location S173Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVIPMFq (+1 to the end of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4670
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KnFSPEVIPMF{t}
Mutations S/T A/N
Epitope Location S+1T A2N
HXB2 Location S173T A163N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KnFSPEVIPMFt (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity without CTLs.


Variant ID.  4671
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVIPMF{v}
Mutations S/V
Epitope Location S+1V
HXB2 Location S173V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVIPMFv (+1 to the end of epitope KF11) had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4672
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  rAFSPEVIPMF{t}
Mutations S/T K/R
Epitope Location S+1T K1R
HXB2 Location S173T K162R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rAFSPEVIPMF{t} (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4673
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFaPEVIPMF{q}
Mutations S/Q S/A
Epitope Location S+1Q S4A
HXB2 Location S173Q S165A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFaPEVIPMFq (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4674
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  rAFSPEVIPMF{q}
Mutations S/Q K/R
Epitope Location S+1Q K1R
HXB2 Location S173Q K162R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rAFSPEVIPMF{q} (+1 to the end of epitope KF11) had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4675
Epitope Seq.  KAFSPEVIPMF{S}
Variant Seq.  KAFSPEVvPMF{a}
Mutations S/A I/V
Epitope Location S+1A I8V
HXB2 Location S173A I169V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVvPMFa (+1 to the end of epitope KF11) had at least a 5-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4676
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFaPEVIPMF
Mutations S/A
Epitope Location S4A
HXB2 Location S165A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFaPEVIPMF had an increased replicative capacity when cultured without CTLs, but did not have an increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones vs. without CTLs.


Variant ID.  4677
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSaEVvPMF
Mutations P/A I/V
Epitope Location P5A I8V
HXB2 Location P166A I169V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSaEVvPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors.


Variant ID.  4678
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KnFSPEVIPMF
Mutations A/N
Epitope Location A2N
HXB2 Location A163N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KnFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors.


Variant ID.  4679
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFqPEVIPMF
Mutations S/Q
Epitope Location S4Q
HXB2 Location S165Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFqPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors.


Variant ID.  4680
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEiIPMF
Mutations V/I
Epitope Location V7I
HXB2 Location V168I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEiIPMF had reduced replicative capacity.


Variant ID.  4681
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  rAFSPEiIPMF
Mutations K/R V/I
Epitope Location K1R V7I
HXB2 Location K162R V168I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rAFSPEiIPMF had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4682
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEtIPMF
Mutations V/T
Epitope Location V7T
HXB2 Location V168T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEtIPMF had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4683
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEVvPMF
Mutations I/V
Epitope Location I8V
HXB2 Location I169V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEVvPMF had at least a 10-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4684
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  rAFaPEVIPMF
Mutations K/R S/A
Epitope Location K1R S4A
HXB2 Location K162R S165A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rAFaPEVIPMF had at least a 2-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4685
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  rAFSPEVIPMF
Mutations K/R
Epitope Location K1R
HXB2 Location K162R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rAFSPEVIPMF had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4686
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  rgFSPEVIPMF
Mutations K/R A/G
Epitope Location K1R A2G
HXB2 Location K162R A163G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rgFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4687
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFcPEVIPMF
Mutations S/C
Epitope Location S4C
HXB2 Location S165C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFcPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4688
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KqFSPEVIPMF
Mutations A/Q
Epitope Location A2Q
HXB2 Location A163Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KqFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4689
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFtPEVIPMF
Mutations S/T
Epitope Location S4T
HXB2 Location S165T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFtPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4690
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KgFaPEVIPMF
Mutations A/G S/A
Epitope Location A2G S4A
HXB2 Location A163G S165A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KgFaPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4691
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KgFSPEVIPMF
Mutations A/G
Epitope Location A2G
HXB2 Location A163G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KgFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4692
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSaEVIPMF
Mutations P/A
Epitope Location P5A
HXB2 Location P166A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSaEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4693
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFmPEVIPMF
Mutations S/M
Epitope Location S4M
HXB2 Location S165M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFmPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4694
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KgFqPEVIPMF
Mutations A/G S/Q
Epitope Location A2G S4Q
HXB2 Location A163G S165Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KgFqPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4695
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KeFSPEVIPMF
Mutations A/E
Epitope Location A2E
HXB2 Location A163E
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KeFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4696
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KsFSPEtIPMF
Mutations A/S V/T
Epitope Location A2S V7T
HXB2 Location A163S V168T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KsFSPEtIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4697
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KdFSPEVIPMF
Mutations A/D
Epitope Location A2D
HXB2 Location A163D
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KdFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4698
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KsFSPEVIPfF
Mutations M/F A/S
Epitope Location M10F A2S
HXB2 Location M171F A163S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KsFSPEVIPfF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4699
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KgFrPEVIPMF
Mutations A/G S/R
Epitope Location A2G S4R
HXB2 Location A163G S165R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KgFrPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4700
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEcIPMF
Mutations V/C
Epitope Location V7C
HXB2 Location V168C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEcIPMF had at least a 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a substantially decreased replicative capacity.


Variant ID.  4701
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFnPEVIPMF
Mutations S/N
Epitope Location S4N
HXB2 Location S165N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFnPEVIPMF had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4702
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KsFSPEVIPMF
Mutations A/S
Epitope Location A2S
HXB2 Location A163S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KsFSPEVIPMF had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by the authors.


Variant ID.  4703
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFvPEVIPMF
Mutations S/V
Epitope Location S4V
HXB2 Location S165V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFvPEVIPMF had a decreased replicative capacity.


Variant ID.  4704
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEcvPMF
Mutations V/C I/V
Epitope Location V7C I8V
HXB2 Location V168C I169V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KAFSPEcvPMF had at least a 2-fold to 5-fold increase in relative enrichment when cultured with each of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity.


Variant ID.  4705
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KtFSPEVIPMF
Mutations A/T
Epitope Location A2T
HXB2 Location A163T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KtFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.


Variant ID.  4706
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KcFSPEVIPMF
Mutations A/C
Epitope Location A2C
HXB2 Location A163C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, KcFSPEVIPMF had at least a 10-fold increase in relative enrichment when cultured with 1 of 2 KAFSPEVIPMF-specific CTL clones, vs. without CTLs, but also had a decreased replicative capacity without CTLs.

References

Gorin2017 Aleksandr M. Gorin, Yushen Du, Franklin Y. Liu, Tian-Hao Zhang, Hwee L. Ng, Christian Hofmann, William G. Cumberland, Ren Sun, and Otto O. Yang. HIV-1 Epitopes Presented by MHC Class I Types Associated with Superior Immune Containment of Viremia Have Highly Constrained Fitness Landscapes. PLoS Pathog, 13(8):e1006541, Aug 2017. PubMed ID: 28787455. Show all entries for this paper.


This is a legacy search page. It is deprecated, will receive no more updates, and will eventually be removed. Please use the new search pages.

Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy's National Nuclear Security Administration
Copyright Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services LANL logo National Institutes of Health logo